A comprehensive view of Horizon Therapeutics Plc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Horizon Therapeutics reports Phase 3 trial shows Uplizna inebilizumab-cdon injectable effective for patients with neuromyelitis optica spectrum disorder after one attack; NMOSD most common in women, people of African, Asian descent

Horizon Therapeutics announces FDA has granted priority review of license application for Krystexxa pegloticase injection plus methotrexate to treat uncontrolled gout; Krystexxa is only approved biologic treatment for gout

Ireland's Horizon Therapeutics submits supplemental biologics license application to US FDA for KRYSTEXXA, or pegloticase injection, with methotrexate for adults with uncontrolled gout; submission based on randomized trial data showing 71% response rate

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count